This is a descriptive observational study, in which data are collected in an EGFR mutant NSCLC. Our research plan aims to use multi-omics approaches to predict the likelihood of patients developing brain metastases, assess the prognosis of brain metastasis treatment, and identify potential biomarkers.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must be ≥18 years.
Provision of fully informed consent prior to any study specific procedures.
Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically. The mutations above may exist alone or together.
Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC).
According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
You may not be if
None
Clareo Health | A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
